A copolymer-based sugar-sensitive microneedle patch containing 3-acrylamidophenylboronic acid

Abstract

The invention discloses a copolymer-based sugar-sensitive microneedle patch containing 3-acrylamidophenylboronic acid. The microneedle patch is composed of a microneedle body and a substrate, the microneedle body and the substrate are 3-acrylamidophenylboronic acid, N-acrylamide-glucose, N-isopropylacrylamide and N,N'-substrate Copolymer of methylbisacrylamide, microneedle body and substrate can load drugs. The preparation method of the invention is simple; at a human body temperature of 37°C, it has suitable mechanical properties, can effectively pierce the skin, and can regulate the release rate and release dose of the drug according to the difference in glucose concentration.

Description

technical field [0001] The invention belongs to the technical field of polymer materials, and in particular relates to a copolymer-based sugar-sensitive microneedle patch containing 3-acrylamidophenylboronic acid. Background technique [0002] Diabetes mellitus is a chronic disease caused by the lack or impairment of insulin secretion function. It is mainly characterized by high blood sugar. In severe cases, it can further induce damage to the functions of the heart, nerves, eyes, and kidneys. According to statistics from the International Diabetes Federation, in 2017, the number of people with diabetes worldwide reached 425 million. With the aggravation of the disease, diabetic patients gradually increase their dependence on antidiabetic drugs, especially exogenous insulin. At present, insulin injection is a common method for diabetic patients to supplement exogenous insulin. However, the pain of injection is obvious, and frequent injections impose a heavy burden on patie...

AI Technical Summary

Problems solved by technology

Chen et al[1] introduced silk fibroin into the precursor solution formulation of phenylboronic acid derivative copolymer-based microneedle patches to improve the mechanical strength of the microneedles. It is greatly suppressed, and it is difficult to meet the actual demand for lowering blood sugar

Yu et al[2] introduced N-vinylpyrrolidone into the precursor solution formulation of phenylboronic acid derivative copolymer-based microneedle patch, and the sugar-sensitive microneedle patch obtained had excellent strength, but insulin inactivation occurred during the preparation process. problem, resulting in less blood sugar-lowering insulin released from the microneedles

Chen Xiang et al. reported a phenylboronic acid hydrogel-based microneedle patch in patent CN109675185A. The microneedle patch exhibited glucose-responsive swelling behavior and drug release behavior at 23°C, but it did not exhibit glucose-responsive swelling behavior and drug release behavior at a human body temperature of 37°C. Does not have the above properties; according to the corresponding document Preparation of phenylboronic acid-based hydrogelmicroneedle patches for glucose-dependent insulin delivery (Figure 5(a)), at 37°C, low sugar (glucose concentration 1g / L) and high sugar (glucose concentration 1g / L) and high sugar ( There is almost no difference in the insulin release curve under the condition of glucose concentration 4g / L), that is, there is no glucose-responsive drug release behavior[3]

Images